BRIEF—Recordati's Isturisa results published

The Journal of Clinical Endocrinology & Metabolism has published positive results from the Phase III LINC 4 study of Recordati’s Isturisa (osilodrostat) in patients with Cushing’s disease.

This study demonstrated the superiority of Isturisa over placebo in achieving cortisol normalization during the 12-week, double-blind, randomised phase.

Isturisa provided rapid and sustained control of cortisol secretion in the majority of patients throughout the 48-week core phase of the trial.

Having been approved in 2020 for the treatment of adult patients with endogenous Cushing’s syndrome in the European Union, Isturisa is now available in France, Germany, Greece and Austria.